HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review.

AbstractBACKGROUND:
The authors compared the relative efficacy and safety of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) for the initial treatment of venous thromboembolism (VTE) between patients with and without cancer.
METHODS:
By using Cochrane methodology for systematic reviews, separate meta-analyses were conducted for subgroups of patients with and without cancer, and relative risks (RRs) were compared for statistical significance. The methodologic quality for each outcome was assessed by using the Grading of Recommendations Assessment, Development, and Evaluation approach.
RESULTS:
LMWH reduced mortality significantly compared with UFH in patients with cancer (RR of 0.71; 95% confidence interval [95% CI], 0.52-0.98 [moderate-quality evidence]) but not in patients without cancer (RR of 0.97; 95% CI, 0.65-1.46 [low-quality evidence]). However, the difference in the RR for the 2 subgroups did not reach statistical significance (P = .113). The difference between LMWH and UFH in the effect on recurrent VTE was not statistically significant in the subgroup with cancer (RR of 0.78; 95% CI, 0.29-2.08 [low-quality evidence]), in the subgroup without cancer (RR of 0.94; 95% CI, 0.60-1.46 [low-quality evidence]), or between the 2 subgroups (P = .367). No data were available for bleeding outcomes, thrombocytopenia, or postphlebitic syndrome.
CONCLUSIONS:
The current results indicated that LMWH most likely is superior to UFH in reducing mortality in the initial treatment of VTE for patients with cancer. There is a need for more and better designed trials to confirm these findings.
AuthorsElie A Akl, Sandeep Rohilla, Maddalena Barba, Francesca Sperati, Irene Terrenato, Paola Muti, Fadi Bdair, Holger J Schünemann
JournalCancer (Cancer) Vol. 113 Issue 7 Pg. 1685-94 (Oct 01 2008) ISSN: 0008-543X [Print] United States
PMID18720360 (Publication Type: Comparative Study, Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't, Review, Systematic Review)
Chemical References
  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Heparin
Topics
  • Anticoagulants (adverse effects, therapeutic use)
  • Heparin (adverse effects, therapeutic use)
  • Heparin, Low-Molecular-Weight (adverse effects, therapeutic use)
  • Humans
  • Neoplasms (complications)
  • Venous Thromboembolism (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: